Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series Ltd: World’s leading Event Organizer

Back

Biography

Harold C. Smith is a tenured full professor of Biochemistry and Biophysics at the University of Rochester School of Medicine and Dentistry and Founder and CEO of OyaGen, Inc.  His expertise is as a cell and molecular biologist with a focus in his research on the structure, function and regulation of nucleic acid protein interactions.  He is an opinion leader on the viral restriction factors known as APOBEC.  OyaGen is a drug discovery and drug development company focused on eradication of HIV/AIDS and other viral diseases through the identification of novel drug targets and small molecules that interact with these targets.

Abstract

Camptothecin (CPT) is a natural product discovered to be active against various cancers through its ability to inhibit Topoisomerase 1 (TOP1).  CPT analogs also have anti-HIV-1 (HIV) activity that has been previously shown not to depend on inhibition of TOP1.  We show that anti-cancer inactive CPT analogs inhibit HIV infection by disrupting homo-oligomerization of an HIV auxiliary protein known as viral infectivity factor (Vif). Antiviral activity depended on the expression of the cellular viral restriction factor known as APOBEC3G (A3G) that, in the absence of functional Vif, has the ability to hypermutate HIV proviral DNA during reverse transcription. Our studies demonstrate that a non-toxic CPT analog (i) prevented Vif multimerization and Vif-dependent A3G degradation, (ii) increased A3G in pseudotyped HIV viral particles along with A3G signature hypermutations in viral genomes, and (iii) possessed an A3G-dependent and broadly neutralizing antiviral activity against seventeen HIV clinical isolates from Groups M (subtypes A-G), N, and O as well as seven single and multi-drug resistant strains of HIV. Medicinal chemistry and structure activity relationship (SAR) efforts further identified a more potent analog that reached a therapeutic index of greater than 1,000 against live HIV subtype A following a single dose in 7-day spreading infections.  We propose that CPT analogs not active against TOP1 have an antiviral mechanism through Vif antagonism that enables A3G-dependent hypermutation of HIV.